Inhibition of p38MAP kinase suppresses fibrogenic reaction in conjunctiva in mice

被引:1
|
作者
Yamanaka, Osamu
Saika, Shizuya
Ohnishi, Yoshitaka
Kim-Mitsuyama, Shokei
Kamaraju, Anil K.
Ikeda, Kazuo
机构
[1] Wakayama Med Univ, Dept Ophthalmol, Wakayama 6410012, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Pharmacol & Mol Therapeut, Kumamoto, Japan
[3] Natl Canc Inst, Lab Cell Regulat & Carcinogenesis, Bethesda, MD USA
[4] Osaka City Univ, Grad Sch Med, Dept Anat, Osaka 558, Japan
来源
MOLECULAR VISION | 2007年 / 13卷 / 190-93期
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: To examine the effects of blocking p38 mitogen-activated protein kinase (MAPK) on post-injury conjunctival scarring in mice. Its effects on the behaviors of cultured subconjunctival fibroblasts were also investigated. Methods: An in vivo study was conducted using an adenoviral vector carrying a dominant-negative (DN)-p38MAPK gene. A circumferential incision was made in the equatorial conjunctiva by scissors in the right eye of generally anesthetized adult C57BL/6 mice. DN-p38MAPK-expressing adenoviral vector was topically applied. The left control eye received non-functioning adenoviral vector. At 2, 5, and 7 days (each, n=22) the eyes were processed for histological or immunohistochemical examination to evaluate the tissue scarring. The expressions of type-I collagen and growth factors were evaluated by real time-reverse transcriptase-polymerase chain reaction. The effects of p38MAPK inhibitor on the proliferation, migration, and fibrogenic gene/protein expression of cultured human fibroblasts were also studied. Results: The in vivo DN-p38MAPK gene introduction blocked the phospho-p38 expression with reduction of myofibroblast generation and suppression of mRNA expression of connective tissue growth factor (CTGF) and monocyte/macrophage chemoattractant protein-1 (MCP-1) in the mouse-injured conjunctiva. Blocking p38MAPK signal in the fibroblasts by a chemical inhibitor counteracted TGF beta 1's enhancement of expressions of type-I collagen, fibronectin, and CTGF. It also retarded cell migration, but cell proliferation was unchanged. Conclusions: Inhibiting p38MAPK signal impairs the fibrogenic reaction induced by the subconjunctival fibroblasts in vivo and in vitro, suggesting its potential effectiveness in preventing excessive scarring following glaucoma filtering surgery.
引用
收藏
页码:1730 / 1739
页数:10
相关论文
共 50 条
  • [31] Tri- and Tetrasubstituted Pyrazole Derivates: Regioisomerism Switches Activity from p38MAP Kinase to Important Cancer Kinases
    Abu Thaher, Bassam
    Arnsmann, Martina
    Totzke, Frank
    Ehlert, Jan E.
    Kubbutat, Michael H. G.
    Schaechtele, Christoph
    Zimmermann, Markus O.
    Koch, Pierre
    Boeckler, Frank M.
    Laufer, Stefan A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (02) : 961 - 965
  • [32] Delayed cardioprotection in a human cardiomyocyte-derived cell line:: the role of adenosine, p38MAP kinase and mitochondrial KATP
    Carroll, R
    Yellon, DM
    BASIC RESEARCH IN CARDIOLOGY, 2000, 95 (03) : 243 - 249
  • [33] Inhibition of p38 MAP kinase- and RICK/NF-κB-signaling suppresses inflammatory bowel disease
    Hollenbach, E
    Neumann, M
    Vieth, M
    Roessner, A
    Malfertheiner, P
    Naumann, M
    FASEB JOURNAL, 2004, 18 (11): : 1550 - +
  • [34] Inhibition of p38 map kinase- and RICK/NF-κB-signaling suppresses inflammatory bowel disease
    Hollenbach, E
    Neumann, M
    Vieth, M
    Roessner, A
    Malfertheiner, P
    Naumann, M
    REGULATORY PEPTIDES, 2004, 122 (01) : 22 - 22
  • [35] Low density lipoproteins inhibit the Na+/H+ antiport in human platelets via activation of p38MAP kinase
    Nofer, JR
    Noll, C
    Feuerborn, R
    Assmann, G
    Tepel, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 340 (03) : 751 - 757
  • [36] Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease
    Marie Fisk
    Parag R. Gajendragadkar
    Kaisa M. Mäki-Petäjä
    Ian B. Wilkinson
    Joseph Cheriyan
    American Journal of Cardiovascular Drugs, 2014, 14 : 155 - 165
  • [37] INHIBITION OF p38 MAP KINASE BY UTILIZING A NOVEL ALLOSTERIC BINDING SITE
    Tong, L.
    Pargellis, C.
    Churchill, L.
    Cirillo, P.
    Gilmore, T.
    Graham, A. G.
    Grob, P. M.
    Hickey, E. R.
    Moss, N.
    Pav, S.
    Regan, J.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2002, 58 : C231 - C231
  • [38] Inhibitors of p38α MAP kinase
    Chakravarty, S
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 37, 2002, 37 : 177 - 186
  • [39] Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition
    Jerome, Kevin D.
    Rucker, Paul V.
    Xing, Li
    Shieh, Huey S.
    Baldus, John E.
    Selness, Shaun R.
    Letavic, Michael A.
    Braganza, John F.
    McClure, Kim F.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (02) : 469 - 473
  • [40] The pharmacokinetics (PK) and pharmacodynamics (PD) of VX-702, a novel, oral p38MAP kinase inhibitor, in healthy volunteers.
    Godfrey, C
    Mohanlal, R
    Merica, E
    Ette, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P52 - P52